Prostate-Specific Antigen
in Urine

Breul, Jürgen; Pickl, Ulrich; Härtung, R.

doi:10.1159/000475336

Cited by 56 publications

(51 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For example, although in their first study Irani et al (34 ) obtained promising results for urinary PSA with 24-h urine samples, in studies using midstream urine samples, results were disappointing (42,43 ). Even in the later multicenter study by Irani et al (36 ), in which they used 12-h urine samples, the good results from the previous study (34 ) were not reproduced.…”

Section: Discussionmentioning

confidence: 98%

Urine Markers as Possible Tools for Prostate Cancer Screening: Review of Performance Characteristics and Practicality

Müller¹,

Brenner²

2006

Clinical Chemistry

View full text Add to dashboard Cite

Background:In recent years, an increasing number of urine-based tests have been proposed as potential screening tests for prostate cancer. The goal of this review was to summarize the current status of evidence regarding performance characteristics of the proposed tests and their practicality under screening conditions. Method: Relevant articles published up to and including May 2005 were identified in the PubMed database. At least 10 cases and 10 controls had to be analyzed for a study to be included in the review. Data concerning the study population, performance characteristics, and the collection and processing of urine samples were extracted from the reviewed articles. Results: In all, 34 retrospective studies evaluating 21 different markers complied with the inclusion criteria. Most of the studies were rather small and included heterogeneous clinical study populations. Promising results were reported for a few markers in single studies, but they have often not been replicated in subsequent larger studies. Some of the more promising results were obtained with 24-h urines or with specimenhandling procedures that might be difficult to perform under screening conditions. Conclusions: Larger studies with a prospective design are required to confirm promising findings regarding performance characteristics of some novel markers recently reported in mostly small studies. Future studies should also pay particular attention to the practicality of the markers under screening conditions.

show abstract

Section: Discussionmentioning

confidence: 98%

Urine Markers as Possible Tools for Prostate Cancer Screening: Review of Performance Characteristics and Practicality

Müller¹,

Brenner²

2006

Clinical Chemistry

View full text Add to dashboard Cite

show abstract

“…Undetectable uPSA associated with a significant decrease in BT was the main observation in a group of 38 patients receiving ADT (data not shown), confirming that production of uPSA by periurethral glands is under androgen control. 7 This observation could explain why 16 patients with detectable uPSA had sPSA that was still undetectable after 6 years; they had normal androgen levels with physiological periurethral gland PSA production but no evidence of disease.…”

Section: Discussionmentioning

confidence: 99%

“…2 Yet, there is no broad consensus among investigators about the particular role for uPSA, suggesting that heterogeneous methodology and technical issues may bias the results of uPSA studies. 3 The method of collection of urine samples has varied considerably among studies, with specimens obtained before and after prostate massage, 4 in first-voided specimens, 2,4,5 in midstream samples [6][7][8] and in 24-hour collections. 9,10 It is quite likely that differences in study methodology are contributing to contradictory results.…”

Section: Introductionmentioning

confidence: 99%

Early detection of prostate cancer local recurrence by urinary prostate-specific antigen

Bolduc

Inman

Lacombe

et al. 2013

CUAJ

View full text Add to dashboard Cite

Purpose: We assessed the role of urinary prostate-specific antigen (uPSA) in the follow-up of prostate cancer after retropubic radical prostatectomy (RRP) for the early detection of local recurrences. Methods:We recruited 50 patients previously treated for prostate cancer with RRP and who had not experienced a prostatespecific antigen (PSA) recurrence within their first postoperative year into a cross-sectional laboratory assessment and prospective 6-year longitudinal follow-up study. We defined biochemical failure as a serum PSA (sPSA) of 0.3 μg/L or greater. Patients provided blood samples and a 50-mL sample of first-voided urine. We performed Wilcoxon rank-sum and Fisher exact tests for statistical analysis. Results:The median sPSA was 0.13 μg/L. The median uPSA was 0.8 μg/L, and was not significantly different when comparing Gleason scores or pathological stages. Of the 50 patients, 27 initially had a nondetectable sPSA but a detectable uPSA, and 11 patients experienced sPSA failure after 6 years. Six patients had detectable sPSA and uPSA initially. Fifteen patients were negative for both sPSA and uPSA, and 13 remained sPSA-free after 6 years. The odds ratio (OR) of having sPSA failure given a positive uPSA test was 4.5 if sPSA was undetectable, but was reduced to 2.6 if sPSA was detectable. The pooled Mantel-Haenszel OR of 4.2 suggested that a detectable uPSA quadrupled the risk of recurrence, independent of whether sPSA was elevated or not. The sensitivity of uPSA for detecting future sPSA recurrences was 81% and specificity was 45%.Conclusion: Urinary PSA could contribute to an early detection of local recurrences of prostate cancer after a radical prostatectomy. RésuméObjectif : Nous avons évalué le rôle de l'antigène prostatique spécifique (APS) urinaire dans le suivi du cancer de la prostate après prostatectomie radicale rétropubienne (PRR) pour le dépistage précoce de récidives locales. Méthodes :

show abstract

“…This leads to increase in serum PSA. (19)(20)(21)(22)(23)(24) However, concomitant decrease in urinary PSA level occurs that is its level decreases in cancerous conditions than in benign conditions (though the actual urinary level remains higher than serum PSA).This has been potentially explained by an altered drainage of prostate secretions in prostatic urethra which leads to decreased excretion of total PSA and thereby increase in serum total PSA. (25) Our findings regarding levels of urinary fPSA in prostatic malignancies compared to benign states of prostate corroborates with Bolduc S et al (2007).…”

Section: Discussionmentioning

confidence: 99%

Can Levels of Urinary Matrix Metalloproteinases (Mmps) Act as an Alternative to Gleason’s Scoring in Prostatic Malignancies

Banerjee¹,

K²,

K³

et al. 2017

jemds

View full text Add to dashboard Cite

show abstract

Prostate-Specific Antigen in Urine

Cited by 56 publications

References 10 publications

Urine Markers as Possible Tools for Prostate Cancer Screening: Review of Performance Characteristics and Practicality

Urine Markers as Possible Tools for Prostate Cancer Screening: Review of Performance Characteristics and Practicality

Early detection of prostate cancer local recurrence by urinary prostate-specific antigen

Can Levels of Urinary Matrix Metalloproteinases (Mmps) Act as an Alternative to Gleason’s Scoring in Prostatic Malignancies

Contact Info

Product

Resources

About